ALNY News and Press, Alnylam Pharmaceuticals Inc. From 03/23/22

Alnylam is an RNA-interference drug developer that was founded in 2002 and joined the Nasdaq in 2004. Alnylam Pharma has been studying Lipid Nanoparticle technology intensively for more than a decade and alleges it once shared its technology with Moderna in 2014. Alnylam is allegi...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2022 CNS Days, being held virtually, on Monday, March 28, 2022 at 2:00 pm ET A live audio webcast of the presentatio...

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) the leading RNAi therapeutics company, announced today that it has separately filed suit in United States District Court for the District of Delaware against Pfizer, Inc. and Moderna, Inc., seeking damages for infringement of U.S. Patent No. ...

–Report Features New Disclosures of Company’s Impact on Planet—Including Scope 1, 2, and Select Scope 3 Greenhouse Gas (GHG) Emissions– – Aligns with the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) R...

FHLC is a well-diversified healthcare ETF concentrated on large caps. FHLC generated strong return, and closely replicated returns of S&P 500. FHLC has strong price multiples and financial growth, at par with peers. For further details see: FHLC: Well Diversified, St...

PTAB turned the CRISPR industry upside down, with sleepy biotechs becoming market favorites overnight and leading companies dropping by double-digit rates. NTLA management will likely talk down the effects of the patent ruling, but given the new dynamics, this speculative trade has be...

Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022. Results from the phase 1a/1b study using AB-729 for Hep B from multiple cohorts are expected at a medical conference in 2022. Results from the ...

The U.S. Food and Drug Administration (FDA) accepted Alnylam Pharmaceuticals (NASDAQ:ALNY) supplemental New Drug Application ((sNDA)) seeking approval of OXLUMO (lumasiran) for reducing plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1 (PH1). The...

PDUFA Date Set for October 6, 2022 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s supplemental New Drug Application (sNDA) for lumasir...

PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...